A Little Trouble For Bristol-Myers (BMY) Plavix

Health and Healthcare

Published: November 4, 2007 5:28 pm

Plavix from Bristol-Myers (BMY) is the medical drug-thinner of choice. According to CNN Money, sales of the drug "totaled $3.4 billion in sales during the first nine months"

Now Eli Lilly (LLY) has a horse in the race. The Associated Press reports that "a new blood thinner proved better than Plavix, one of the world’s top-selling drugs, at preventing heart problems after procedures to open clogged arteries." The news services added people given the experimental drug, prasugrel, were nearly 20 percent less likely to suffer one of the problems in a combined measure — heart attack, stroke or heart-related death — than those given Plavix, a drug that millions of Americans take to prevent blood clots that cause these events.

Lilly could use a little help. Its shares are flat this year, while Bristol-Myers is up over 10%.

The problems with these new drugs and treatments is always the same. They solve one problem, but cause another. Patients taking prasugrel are more likely to die from bleeding.

Oh, well.

Douglas A. McIntyre

Are You Still Paying With a Debit Card?

The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.

Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!

Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!

Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.